Search Clinical Trials
By Condition
By Location (USA)
By Location (Other)
By Sponsor
Resources
Privacy Policy
About Us
Disclaimer
Brain Blood Flow Studies of Language and Memory Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, trips or professional assistance with a real medical doctor. We aren't docs. Always confer with your doctor about Brain Blood Flow Studies of Language and Memory conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Brain Blood Flow Studies of Language and Memory Clinical research trials and Brain Blood Flow Studies of Language and Memory health trials happen in many of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the effectualness of new does drugs. The intention of the studies / projects is to figure out particular human healthcare questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to detect cures for all forms of circumstances, like Brain Blood Flow Studies of Language and Memory. Brain Blood Flow Studies of Language and Memory Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment options before they are available to the general public. Most times the subjects get treatment for free of charge, and occasionally they are paid for their time. Occasionally there is a cost for a Brain Blood Flow Studies of Language and Memory clinical trial. Subjects frequently get the best healthcare possible for their Brain Blood Flow Studies of Language and Memory condition. Hazards are a reality, however, and could include more or frequent mD visits, health risks (possibly life-jeopardizing), and/or the treatment being ineffectual. Trials are federally regulated with exacting guidelines to protect clinical trials patients.

Home > "B" Clinical Trials Conditions > Brain Blood Flow Studies of Language and Memory

Brain Blood Flow Studies of Language and Memory



Brain Blood Flow Studies of Language and Memory

For Condition: Cerebrovascular Disorder,Epilepsy
Status: Completed
Sponsor(s): National Institute of Neurological Disorders and Stroke (NINDS) ,
Synopsis: Positron Emission Tomography (PET) is a technique used to investigate the functional activity of the brain. The PET technique allows doctors to study the normal processes of the brain (central nervous system) of normal individuals and patients with neurologic illnesses without physical / structural damage to the brain. When a region of the brain is active, it uses more fuel in the form of oxygen and sugar (glucose). As the brain uses more fuel it produces more waste products, carbon dioxide and water. Blood carries fuel to the brain and waste products away from the brain. As brain activity increases blood flow to and from the area of activity increases also. Knowing these facts, researchers can use radioactive water (H215O) and PET scans to observe what areas of the brain are receiving more blood flow. This study is designed to use positron emission tomography (PET) with radioactive water (H215O) to determine the areas of the brain associated with memory and language. Patients participating in the study will be made up of normal volunteers, patients with epilepsy, and patients with other abnormalities related to the surface of the brain (non-epileptic focal cortical dysfunctions).
Details: This protocol will use positron emission tomography (PET) with H2015 and functional MRI to examine localization of memory and language in normal control subjects, and patients with localization-related epilepsy.
Eligibility:
Study Type:
  Observational, Natural History
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: INCLUSION CRITERIA: Normal Volunteers: The desired age range is 18 to 55 years. Subjects will have no history of head injury or other neurological disease and must not be taking any medication. Female subjects of childbearing potential will be administered a pregnancy test; these subjects will not be eligible for the study requiring 2 scans. All volunteers will read and sign the consent form. Patients: Patients will be selected from among those referred to the Clinical Epilepsy Section, NINDS for evaluation. EXCLUSION CRITERIA: Patients with evidence of a progressive intracranial process, who are taking any drugs (except AEDs) that might affect the results, or active systemic disease will be excluded.
Total Enrollment: 303

Location and Contact Information:

National Institute of Neurological Disorders and Stroke (NINDS)
Bethesda,  Maryland,  20892
United States
 


Additional Information:
Study ID Numbers:
  910134;  91-N-0134
Study Start Date: May 15, 1991
Record last reviewed: June 4, 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001288

Other Epilepsy Studies:
1. Measurement Of Serum Levels Of Two Antiepileptic Drugs During Conversion In Patients With Epilepsy.

2. Genetic Study of Familial Epilepsy

3. Depression and Health Outcomes in Refractory Epilepsy

4. Randomized Study of Albendazole in Patients with Epilepsy Due to Neurocysticercosis

5. Mapping the Areas of the Brain Associated with Language in Children with Epilepsy

Related Studies:

Other Epilepsy Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials

Brain Blood Flow Studies of Language and Memory

Modify your Search

  Other Epilepsy Clinical Trials
  Other Maryland Clinical Trials
  Other Bethesda Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103